Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMartín, María C.
dc.contributor.authorJurado, Aurora
dc.contributor.authorAbad Molina, Cristina
dc.contributor.authorOrduña, Antonio
dc.contributor.authorYarce, Oscar
dc.contributor.authorNavas, Ana M.
dc.contributor.authorHernández González, Manuel
dc.contributor.authorPerurena Prieto, Janire
dc.date.accessioned2022-01-13T17:53:51Z
dc.date.available2022-01-13T17:53:51Z
dc.date.issued2021-05-20
dc.identifier.citationMartín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making. Immun Ageing. 2021 May 20;18:24.
dc.identifier.issn1742-4933
dc.identifier.urihttps://hdl.handle.net/11351/6797
dc.descriptionCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Immunosenescence; Lockdown
dc.description.abstractBackground One hundred fifty million contagions, more than 3 million deaths and little more than 1 year of COVID-19 have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 severity. Two main reasons underlie this: immunosenescence and age correlation with main COVID-19 comorbidities such as hypertension or dyslipidaemia. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data. Results Concerning the characteristics of lockdown series, mild cases accounted for 14.4, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age > 60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6, CRP, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 and CD8 count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. IL-6, CRP and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 T-cell count below 535 cells/μL, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve. Conclusion Age and sex together with selected laboratory parameters on admission can help us predict COVID-19 severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown might affect the homogeneity of the data and the robustness of the results.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesImmunity & Ageing;18
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Epidemiologia
dc.subjectMedicina clínica - Presa de decisions
dc.subjectCOVID-19 (Malaltia) - Factors de risc
dc.subject.meshCoronavirus Infections
dc.subject.mesh/epidemiology
dc.subject.meshClinical Decision-Making
dc.subject.meshSeverity of Illness Index
dc.titleThe age again in the eye of the COVID-19 storm: evidence-based decision making
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12979-021-00237-w
dc.subject.decsinfecciones por Coronavirus
dc.subject.decs/epidemiología
dc.subject.decstoma de decisiones clínicas
dc.subject.decsíndice de la gravedad de la enfermedad
dc.relation.publishversionhttps://doi.org/10.1186/s12979-021-00237-w
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Martín MC] Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain. [Jurado A, Yarce O, Navas AM] Department of Immunology and Allergology, Hospital Universitario Reina Sofía-Instituto de Investigación Biomédica de Córdoba (IMIBIC), 14004 Córdoba, Spain. [Abad-Molina C, Orduña A] Department of Microbiology and Immunology, Hospital Clínico Universitario, Valladolid, Spain. [Hernández M, Perurena-Prieto J] Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34016150
dc.identifier.wos000652608400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record